US FDA shapes new drug inspections plan; asserts no India 'agenda'
This article was originally published in SRA
Executive Summary
Pharmaceutical firms that pose minimal quality compliance risks could potentially attract a reduced frequency of inspections by the US Food and Drug Administration under the agency's proposed new "carrot and stick" approach to facility audits.